International Journal of Biological Sciences

Impact factor
3.873

ISSN 1449-2288

News feeds of IJBS published articles
My Manuscript
My Account

Journal of Biomedicinenew

Theranostics

International Journal of Medical Sciences

Journal of Cancer

Oncomedicine

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

PubMed Central Indexed in Journal Impact Factor

Int J Biol Sci 2010; 6(6):590-598. doi:10.7150/ijbs.6.590

Communication

Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests

Joël Spiroux de Vendômois1, Dominique Cellier1,2, Christian Vélot1,3, Emilie Clair1,4, Robin Mesnage1,4, Gilles-Eric Séralini1,4

1. CRIIGEN, 40 rue Monceau, 75008 Paris France
2. University of Rouen, LITIS EA 4108, 76821 Mont Saint-Aignan, France
3. University Paris-Sud, Bâtiment 360 91405 Orsay, France
4. University of Caen, Institute of Biology, Risk Pole MRSH CNRS, EA2608, Esplanade de la Paix 14032 Caen Cedex, France

Abstract

We summarize the major points of international debate on health risk studies for the main commercialized edible GMOs. These GMOs are soy, maize and oilseed rape designed to contain new pesticide residues since they have been modified to be herbicide-tolerant (mostly to Roundup) or to produce mutated Bt toxins. The debated alimentary chronic risks may come from unpredictable insertional mutagenesis effects, metabolic effects, or from the new pesticide residues. The most detailed regulatory tests on the GMOs are three-month long feeding trials of laboratory rats, which are biochemically assessed. The tests are not compulsory, and are not independently conducted. The test data and the corresponding results are kept in secret by the companies. Our previous analyses of regulatory raw data at these levels, taking the representative examples of three GM maize NK 603, MON 810, and MON 863 led us to conclude that hepatorenal toxicities were possible, and that longer testing was necessary. Our study was criticized by the company developing the GMOs in question and the regulatory bodies, mainly on the divergent biological interpretations of statistically significant biochemical and physiological effects. We present the scientific reasons for the crucially different biological interpretations and also highlight the shortcomings in the experimental protocols designed by the company. The debate implies an enormous responsibility towards public health and is essential due to nonexistent traceability or epidemiological studies in the GMO-producing countries.

Keywords: GMOs, Health risks, Pesticides, Regulatory toxicology, Animal tests

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
de Vendômois JS, Cellier D, Vélot C, Clair E, Mesnage R, Séralini GE. Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests. Int J Biol Sci 2010; 6(6):590-598. doi:10.7150/ijbs.6.590. Available from http://www.ijbs.com/v06p0590.htm